Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 19;59(1):617–626. doi: 10.1080/13880209.2021.1923759

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Patterns of mRNA level changes in the Hippo signalling pathway induced by Lappaol F (LAF). For transcriptome analysis, SW480 cells were treated with 50 µmol/L LAF for 12, 24 or 36 h. For quantitative RT-PCR, cancer cells (HeLa, MDA-MB-231, SW480 and PC3) were treated with 50 µmol/L LAF for 36 h. (A) Differentially expressed genes (fold change ≥ 2 and false discovery rate < 0.01) involved in the Hippo pathway. (B) YAP mRNA levels measured by quantitative RT-PCR. (C) 14-3-3σ mRNA levels measured by quantitative RT-PCR. All data are expressed as the mean ± SD (transcriptomic analysis, n = 3; quantitative RT-PCR, n = 6). **p < 0.01, significantly different from the control without LAF treatment. AREG: amphiregulin; Axin2: axis inhibition protein 2; Bcl-2: B cell lymphoma/leukemia-2; BIRC5: survivin/baculoviral IAP repeat containing 5; c-Myc: cellular myelocytomatosis oncogene; GLI2: glioma-associated oncogene family zinc finger 2; YAP: Yes-associated protein.